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Author’s response
Firstly, I would like to thank Dr. vd Woude for her
well-documented and challenging remarks on our
study. Her statement however that there exists no
dose dependency between the effect (FEV1) and
the administered dose, cannot be excluded by the
references she quoted. Firstly, there are other
references which have not been quoted, which do
sustain the perception that there is a dose
dependency as mentioned.1–3 Secondly, neither of
these studies, including ours, is designed to
determine the pharmacological potency of this
drug. For this pharmacodynamic and pharmacoki-
netic studies are necessary, which have been
performed by our group,4 illustrating that not only
a concentration effect relationship may exist,
moreover this relationship seems to be dependent
of inhaled fraction, when considering the onset of
action and the oropharyngeal deposited fraction, as
far as the length of the bronchodilating effect is
concerned. Even more, these studies leave out the
influence of formoterol being a racemate, existing
of RR (effective) and SS enantiomers (far less
effective).5,6
Our study was designed to show a clinical dose
equivalence of a new multi dose inhaler (Airmaxs)
compared to the originally registered device
(Aerolizers), as has been done before with other
mdpi devices7. The cumulative dose design was
adapted from earlier studies2,3 and did show a step-
by-step dose dependency in both arms in a 1:2
ratio. We did not continue measurements after
4:30 h, because we did not expect the maximal
achievable FEV1 to be different since in both arms
the maximal dose effect was achieved. We agree
with Dr. van der Woude that statistical and clinical
significant difference in dose–response can only be
demonstrated with a significant shift in the dose–
reponse curve. However, we did not show any
significant shifts between the cumulative dose–
response curves. It would have been illustrative to
compare the novel device with the Aerolizers 6
mcg, however, this formulation does not exist.
Within the limits of the study design, not being a
pharmacodynamic and pharmacokinetic study, we
maintain our conclusions of the study.
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